methyl 2-[5,7-dimethyl-3-[2-[[(2R)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]-2-oxobenzimidazol-1-yl]acetate | 1087234-08-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[5,7-dimethyl-3-[2-[[(2R)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]-2-oxobenzimidazol-1-yl]acetate
• CAS: 1087234-08-9
• 化学式: C₂₆H₂₇N₅O₆
• 分子量: 505.53
• InChiKey: DVWHBSJZSHVOSH-AREMUKBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (R)-5'-amino-3-methyl-spiro[imidazolidine-4,2'-indane]-2,5-dione 、 [3-(2-methoxy-2-oxoethyl)-4,6-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]acetic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-[5,7-dimethyl-3-[2-[[(2R)-1'-methyl-2',4'-dioxospiro[1,3-dihydroindene-2,5'-imidazolidine]-5-yl]amino]-2-oxoethyl]-2-oxobenzimidazol-1-yl]acetate
  参考文献：
  名称：

  Potent benzimidazolone-based CGRP receptor antagonists

  摘要：

  The previously disclosed spirohydantoin-based CGRP receptor antagonists were optimized for potency through modi. cation of the benzimidazolone substituents. Compounds were identified which had minimal shift in the cAMP functional assay containing 50% human serum. Blockade of CGRP-mediated vasodilation was observed with these compounds in a rhesus pharmacodynamic assay and the in vivo potency correlated with the in vitro activity in the serum-shifted functional assay. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.019

文献信息

• Potent benzimidazolone-based CGRP receptor antagonists
  作者：Cory R. Theberge、Rodney A. Bednar、Ian M. Bell、Halea A. Corcoran、John F. Fay、James C. Hershey、Victor K. Johnston、Stefanie A. Kane、Scott Mosser、Christopher A. Salvatore、Theresa M. Williams、C. Blair Zartman、Xu-Fang Zhang、Samuel L. Graham、Joseph P. Vacca

  DOI：10.1016/j.bmcl.2008.10.019

  日期：2008.12

  The previously disclosed spirohydantoin-based CGRP receptor antagonists were optimized for potency through modi. cation of the benzimidazolone substituents. Compounds were identified which had minimal shift in the cAMP functional assay containing 50% human serum. Blockade of CGRP-mediated vasodilation was observed with these compounds in a rhesus pharmacodynamic assay and the in vivo potency correlated with the in vitro activity in the serum-shifted functional assay. (C) 2008 Elsevier Ltd. All rights reserved.